1.
Trends in Management and Outcomes of ST-Elevation Myocardial Infarction in Patients With End-Stage Renal Disease in the United States
by Gupta, Tanush, MD
The American journal of cardiology, 2015, Vol.115 (8), p.1033-1041
2.
Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine
by Kuan, Renee Kim
Vaccine, 2013, Vol.31 (37), p.4024-4032
3.
The Affordable Dialysis Prize steams ahead
by Knight, John
The Lancet (British edition), 2016, Vol.387 (10023), p.1040-1040
4.
Medical Neighborhood Model for the Care of Chronic Kidney Disease Patients
by Smith, Zoe G
American journal of nephrology, 2016, Vol.44 (4), p.308-315
5.
Renal replacement therapy: how can we contain the costs?
by Vanholder, Raymond
The Lancet (British edition), 2014, Vol.383 (9931), p.1783-1785
6.
Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis,...
by Dore, David D
Journal of clinical epidemiology, 2013, Vol.66 (8), p.S42-S50
7.
Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study
by Lamping, Donna L
The Lancet (British edition), 2000, Vol.356 (9241), p.1543-1550
8.
Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-stage Renal Disease
by Keith, Michael S., PharmD, PhD
Clinical therapeutics, 2014, Vol.36 (9), p.1276-1286
9.
Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Dialysis Patients: A Canadian Payer Perspective
by Vegter, Stefan, PharmD, PhD
Clinical therapeutics, 2012, Vol.34 (7), p.1531-1543
10.
Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney
by Grima, Daniel T
Current medical research and opinion, 2011, Vol.27 (2), p.383-391
11.
Real-World Dose-Relativity, Tablet Burden, and Cost Comparison of Conversion Between Sevelamer Hydrochloride/Carbonate and Lanthanum Carbonate Monotherapies
by Keith, Michael S., PharmD, PhD
Clinical therapeutics, 2014, Vol.36 (10), p.1431-1442.e1
12.
Timing of Arteriovenous Fistula Placement and Medicare Costs during Dialysis Initiation
by Solid, Craig A
American journal of nephrology, 2012, Vol.35 (6), p.498-508
13.
Peritoneal Dialysis: Misperceptions and Reality
by Saxena, Ramesh, MD, PhD
The American journal of the medical sciences, 2014, Vol.348 (3), p.250-261
14.
Haemodialysis: hospital or home?
by Power, Albert
Postgraduate Medical Journal, 2014, Vol.90 (1060), p.92-97
15.
The financial implications for medicare of greater use of peritoneal dialysis
by Neil, Nancy, PhD
Clinical therapeutics, 2009, Vol.31 (4), p.880-888
16.
Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure
by Avorn, Jerry
Journal of clinical epidemiology, 2002, Vol.55 (7), p.711-716
17.
Cost of managing anemia in end-stage renal disease: the experience of five French dialysis centers
by Rottembourg, Jacques
The European journal of health economics, 2014, Vol.16 (4), p.357-364
18.
Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients
by Schumock, Glen T
Current medical research and opinion, 2008, Vol.24 (11), p.3037-3048
19.
Anemia Management Trends in Hospital-Based Dialysis Centers (HBDCs), 2010 to 2013
by Coritsidis, George N., MD
Clinical therapeutics, 2014, Vol.36 (3), p.408-418
20.
China's organ transplant system in transition
by Alcorn, Ted
The Lancet (British edition), 2011, Vol.377 (9781), p.1905-1906
